#SueWallst Logo

Biohaven Ltd. Investigation

Company: Biohaven Ltd.

Ticker: (NYSE) BHVN

How to Check Whether You May Be Eligible in the Biohaven Ltd. Investigation

There is no cost or obligation for you to submit.

The submission of this form does not create an attorney-client relationship.

Investigation Details

Biohaven Ltd. shares fell 14.73% on September 10, 2026, following a partial clinical hold issued by the FDA on the Company's BHV-7000/opakalim program, pausing new patient enrollment. The FDA reportedly “determined that there was insufficient information related to a specific metabolite to assess risks" of a "certain metabolites of BHV-7000 observed in rodent testing." This follows the August 26 announcement of a licensing agreement for Biohaven's Kv7 ion channel platform, led by opakalim.